Free Trial
→ The one number Musk can't hide in the S-1 (From Behind the Markets) (Ad)tc pixel Free MREO Stock Alerts

Mereo BioPharma Group (MREO) Financials

Mereo BioPharma Group logo
$0.26 +0.01 (+5.49%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$0.26 0.00 (-0.96%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Mereo BioPharma Group

Annual Income Statements for Mereo BioPharma Group

This table shows Mereo BioPharma Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -35 -52 -42 -49 -447 34 -42 -29 -43
Consolidated Net Income / (Loss)		 -35 -52 -41 -46 -223 17 -42 -29 -43
Net Income / (Loss) Continuing Operations		 -35 -52 -42 -49 -223 17 -42 -29 -43
Total Pre-Tax Income 		-42 -63 -48 -54 -223 17 -43 -30 -43
Total Operating Income		 -45 -61 -44 -52 -47 -30 -54 -28 -47
Total Gross Profit		 0.00 0.00 0.00 0.00 3.91 23 1.15 7.43 0.00
Total Revenue		 0.00 0.00 0.00 0.00 3.91 47 0.00 10 0.00
Operating Revenue		 - - - 0.00 3.91 47 0.00 10 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 24 -1.15 2.57 0.00
Operating Cost of Revenue		 - - - 0.00 0.00 24 -1.15 2.57 0.00
Total Operating Expenses		 45 61 44 52 51 53 56 36 47
Selling, General & Admin Expense		 14 14 15 21 29 22 26 18 26
Research & Development Expense		 30 47 29 31 22 32 29 17 21
Total Other Income / (Expense), net		 3.03 -2.22 -4.51 -4.65 -176 47 11 -1.57 4.11
Interest Expense		 0.22 1.47 4.85 5.79 - - 4.18 2.88 1.37
Interest & Investment Income		 0.46 1.12 0.39 0.50 - - 0.84 2.13 3.04
Other Income / (Expense), net		 2.79 -1.87 -0.06 0.64 -176 47 15 -0.82 2.44
Income Tax Expense		 -6.58 -11 -6.72 -8.31 - - -0.72 -0.53 0.00
Other Gains / (Losses), net		 - - - - - - - -0.01 0.00
Basic Earnings per Share		 - ($0.56) ($0.45) ($0.39) - - ($0.07) ($0.04) ($0.06)
Weighted Average Basic Shares Outstanding		 - - 71.24M 97.96M -0.48 0.02 603.20M 659.45M 739.62M
Diluted Earnings per Share		 - ($0.56) ($0.45) ($0.39) - - ($0.07) ($0.04) ($0.06)
Weighted Average Diluted Shares Outstanding		 - - 71.24M 97.96M 338.95M 584.91M 603.20M 659.45M 739.62M
Weighted Average Basic & Diluted Shares Outstanding		 - - 71.24M 97.96M 338.95M 584.91M 624.93M 701.29M 795.00M

Quarterly Income Statements for Mereo BioPharma Group

This table shows Mereo BioPharma Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -9.80 -1.75 -6.53 -11 -8.95 -12 -15 -7.05
Consolidated Net Income / (Loss)		 -12 -1.75 -6.53 -9.11 -8.95 -12 -15 -7.05
Net Income / (Loss) Continuing Operations		 -12 -1.75 -6.53 -9.12 -8.95 -12 -15 -7.05
Total Pre-Tax Income 		-12 -1.75 -6.53 -9.64 -8.95 -12 -15 -7.05
Total Operating Income		 -11 -0.81 -9.07 -7.13 -9.90 -13 -9.37 -15
Total Operating Expenses		 12 6.38 9.30 8.06 9.90 13 9.37 15
Selling, General & Admin Expense		 6.45 2.67 5.71 3.60 5.91 7.87 6.20 6.46
Research & Development Expense		 5.31 3.71 3.59 4.81 3.99 4.95 3.17 8.82
Total Other Income / (Expense), net		 0.04 -0.94 2.54 -3.21 0.95 0.56 -5.63 8.23
Interest Expense		 0.80 1.03 0.70 0.35 0.31 0.33 0.35 0.38
Interest & Investment Income		 0.31 0.37 0.69 0.76 0.62 0.56 0.98 0.88
Other Income / (Expense), net		 0.54 -0.28 2.55 -3.62 0.64 0.33 -6.26 7.73
Basic Earnings per Share		 ($0.02) $0.00 ($0.01) ($0.01) ($0.01) ($0.02) ($0.02) ($0.01)
Weighted Average Basic Shares Outstanding		 623.93M 628.42M 684.97M 659.45M 700.26M 711.77M 770.15M 739.62M
Diluted Earnings per Share		 ($0.02) $0.00 ($0.01) ($0.01) ($0.01) ($0.02) ($0.02) ($0.01)
Weighted Average Diluted Shares Outstanding		 623.93M 628.42M 684.97M 659.45M 700.26M 711.77M 770.15M 739.62M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 701.29M 701.36M 769.26M 775.73M 795.00M

Annual Cash Flow Statements for Mereo BioPharma Group

This table details how cash moves in and out of Mereo BioPharma Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 48 -2.90 -32 -11 36 97 -47 -11 12
Net Cash From Operating Activities		 -37 -43 -29 -61 2.18 -8.17 -49 -21 -33
Net Cash From Continuing Operating Activities		 -35 -44 -28 -55 2.18 -8.17 -49 -21 -33
Net Income / (Loss) Continuing Operations		 -42 -63 -48 -54 0.00 0.00 -42 -29 -43
Consolidated Net Income / (Loss)		 -42 -63 -48 -54 - - -42 -29 -43
Depreciation Expense		 0.04 0.05 0.05 2.09 2.18 - 0.18 0.17 0.14
Amortization Expense		 - - - - - - 0.71 0.89 0.95
Non-Cash Adjustments To Reconcile Net Income		 5.44 8.28 6.03 6.45 - -8.17 -9.48 9.32 8.35
Changes in Operating Assets and Liabilities, net		 1.17 11 13 -8.74 - - 1.99 -2.05 1.28
Net Cash From Investing Activities		 0.46 -5.06 0.32 57 0.00 -0.72 1.99 -0.42 -0.70
Net Cash From Continuing Investing Activities		 0.46 -5.06 0.32 44 0.00 -0.72 1.99 -0.42 -0.70
Acquisitions		 - - - - - - 0.00 -0.42 -0.70
Net Cash From Financing Activities		 84 46 -2.64 -7.57 34 106 0.20 7.97 46
Net Cash From Continuing Financing Activities		 84 46 -2.05 -7.57 34 106 0.20 7.97 46
Repayment of Debt		 0.00 -0.71 -2.10 -5.24 -27 0.00 0.00 -3.22 0.00
Repurchase of Common Equity		 -3.70 -0.99 -0.40 -2.33 - - 0.00 -0.51 -0.85
Issuance of Common Equity		 84 20 0.35 0.00 0.00 - 0.20 12 47
Effect of Exchange Rate Changes		 - - - - - - - 2.82 -0.23
Cash Interest Paid		 - - - - 3.96 0.00 0.02 0.88 0.02
Cash Income Taxes Paid		 - - - - - - 1.88 -1.34 0.00

Quarterly Cash Flow Statements for Mereo BioPharma Group

This table details how cash moves in and out of Mereo BioPharma Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -9.67 -7.69 12 -5.11 -8.69 39 -7.09 -11
Net Cash From Operating Activities		 -9.25 -7.75 2.66 -6.79 -7.99 -7.90 -7.52 -9.42
Net Cash From Continuing Operating Activities		 -9.25 -7.75 2.66 -6.79 -7.99 -7.90 -7.52 -9.12
Net Income / (Loss) Continuing Operations		 -12 -1.75 -6.53 -9.11 -8.95 -12 -15 -7.05
Consolidated Net Income / (Loss)		 -12 -1.75 -6.53 -9.11 -8.95 -12 -15 -7.05
Depreciation Expense		 0.04 0.04 0.05 0.04 0.04 0.02 0.04 0.04
Amortization Expense		 0.19 0.23 0.24 0.24 0.23 0.23 0.24 0.24
Non-Cash Adjustments To Reconcile Net Income		 1.73 1.33 1.43 4.83 1.56 2.22 8.35 -3.78
Changes in Operating Assets and Liabilities, net		 0.87 -7.60 7.48 -2.79 -0.87 1.88 -1.16 1.43
Net Cash From Financing Activities		 0.00 0.07 7.91 - 0.00 47 -0.59 -0.04
Net Cash From Continuing Financing Activities		 0.00 0.07 7.91 - 0.00 47 -0.59 -0.04
Effect of Exchange Rate Changes		 - - - 1.68 - - - -1.26
Cash Interest Paid		 0.68 0.18 0.00 0.02 0.00 0.01 - 0.01

Annual Balance Sheets for Mereo BioPharma Group

This table presents Mereo BioPharma Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 130 86 115 86 171 77 66 76
Total Current Assets		 85 44 40 41 134 75 64 75
Cash & Equivalents		 68 32 22 32 127 68 57 70
Prepaid Expenses		 2.66 1.36 2.80 2.21 3.78 5.45 5.16 2.18
Other Current Assets		 - - - - - 1.57 1.18 2.79
Plant, Property, & Equipment, net		 0.21 0.19 15 2.15 3.42 0.55 0.41 0.26
Total Noncurrent Assets		 45 42 59 43 33 1.67 2.33 1.37
Intangible Assets		 45 42 59 43 33 0.00 1.09 0.64
Other Noncurrent Operating Assets		 - - - - - 1.67 1.25 0.73
Total Liabilities & Shareholders' Equity		 130 86 107 86 165 77 66 76
Total Liabilities		 46 44 61 106 52 26 16 15
Total Current Liabilities		 13 21 40 12 17 24 9.49 14
Short-Term Debt		 2.62 8.71 20 - 0.00 13 0.00 5.54
Accounts Payable		 4.09 5.82 8.42 4.55 3.37 3.49 2.35 2.44
Accrued Expenses		 5.92 5.65 - 5.71 - 5.44 5.47 4.07
Other Current Liabilities		 0.37 0.42 3.84 1.44 6.34 2.12 1.67 1.80
Total Noncurrent Liabilities		 33 23 22 95 35 1.64 6.48 1.57
Long-Term Debt		 25 19 7.12 22 19 0.00 4.39 0.00
Other Noncurrent Operating Liabilities		 7.32 4.69 2.15 71 13 1.64 2.08 1.57
Commitments & Contingencies		 - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 84 42 53 -20 119 51 51 61
Total Preferred & Common Equity		 84 42 53 -20 119 51 51 61
Total Common Equity		 -75 -109 -108 -241 -215 51 51 61
Common Stock		 0.29 0.27 0.39 1.39 2.37 479 489 543
Retained Earnings		 -107 -142 -194 -423 -401 -405 -420 -463
Treasury Stock		 0.00 -0.39 -1.73 -1.78 -1.54 -1.34 -1.23 0.00
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -22 -17 -19

Quarterly Balance Sheets for Mereo BioPharma Group

This table presents Mereo BioPharma Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024
Period end date 3/31/2024 6/30/2024 9/30/2024
Total Assets		 56 96 89
Total Current Assets		 53 94 87
Cash & Equivalents		 49 87 81
Prepaid Expenses		 3.19 4.49 3.83
Other Current Assets		 1.65 2.02 2.37
Plant, Property, & Equipment, net		 0.36 0.34 0.32
Total Noncurrent Assets		 2.08 1.85 1.71
Intangible Assets		 0.97 0.87 0.80
Other Noncurrent Operating Assets		 1.11 0.99 0.91
Total Liabilities & Shareholders' Equity		 56 96 89
Total Liabilities		 13 17 16
Total Current Liabilities		 11 15 14
Short-Term Debt		 4.63 4.93 5.55
Accounts Payable		 2.46 2.70 1.75
Accrued Expenses		 2.54 3.72 3.53
Other Current Liabilities		 1.38 4.11 3.38
Total Noncurrent Liabilities		 2.10 2.01 2.00
Long-Term Debt		 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 2.10 2.01 2.00
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 43 79 73
Total Preferred & Common Equity		 43 79 73
Total Common Equity		 43 79 73
Common Stock		 490 538 539
Retained Earnings		 -429 -441 -456
Treasury Stock		 0.00 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -18 -18 -11

Annual Metrics And Ratios for Mereo BioPharma Group

This table displays calculated financial ratios and metrics derived from Mereo BioPharma Group's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1,105.41% -100.00% 0.00% -100.00%
EBITDA Growth		 0.00% -50.74% 30.29% -12.98% -345.84% 107.76% -325.36% 27.22% -55.57%
EBIT Growth		 0.00% -50.71% 30.27% -17.61% -332.05% 107.69% -330.53% 26.17% -53.65%
NOPAT Growth		 0.00% -37.10% 28.23% -19.21% 9.49% 8.64% -25.70% 47.79% -66.68%
Net Income Growth		 0.00% -49.63% 22.15% -13.15% -384.00% 107.69% -345.77% 30.21% -46.79%
EPS Growth		 0.00% 0.00% 19.64% 13.33% 0.00% 0.00% 0.00% 42.86% -50.00%
Operating Cash Flow Growth		 0.00% -18.66% 32.12% -106.46% 103.59% -474.13% -497.55% 56.72% -55.38%
Free Cash Flow Firm Growth		 0.00% 0.00% 72.34% -247.80% 191.46% -204.66% 79.15% -28.82% -55.10%
Invested Capital Growth		 0.00% 0.00% -17.91% 130.62% -136.79% 163.92% -118.72% 27.91% -32.45%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.80%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.66%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -20.78%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.55%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.71%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -35.44%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 48.76% 0.00% 74.26% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -5,653.49% 36.41% 0.00% -281.77% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -1,210.85% -64.24% 0.00% -284.16% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -5,709.28% 36.41% 0.00% -292.38% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -5,709.28% 36.41% 0.00% -294.66% 0.00%
Tax Burden Percent		 84.19% 82.64% 85.85% 84.74% 100.00% 100.00% 98.33% 98.23% 100.00%
Interest Burden Percent		 99.42% 100.56% 108.06% 105.34% 100.00% 100.00% 108.42% 102.60% 96.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -133.73% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -2,410.19% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% -1,224.89% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -62.09% -64.69% -97.11% -1,358.62% 34.93% -49.61% -57.81% -77.58%
Cash Return on Invested Capital (CROIC)		 0.00% -406.66% -61.78% -144.17% 0.00% -420.68% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -222.89% 13.39% 0.00% -40.63% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -222.89% 13.39% 0.00% -40.95% 0.00%
Return on Common Equity (ROCE)		 0.00% 55.40% 94.61% 221.71% 14,425.93% -162.19% 47.76% -57.81% -77.58%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -62.09% -97.74% -86.56% 1,092.97% 14.46% -82.14% -58.31% -70.94%
Net Operating Profit after Tax (NOPAT)		 -31 -43 -31 -37 -33 -30 -38 -20 -33
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -847.60% -64.24% 0.00% -198.91% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -44.58% -39.70% 109.22% 2,276.45% 87.31% -5.31% -17.75% -17.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -36.21% -49.85%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 51.24% 0.00% 25.74% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 740.47% 45.59% 0.00% 184.24% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 570.38% 67.41% 0.00% 174.18% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 1,310.85% 113.00% 0.00% 358.42% 0.00%
Earnings before Interest and Taxes (EBIT)		 -42 -63 -44 -52 -223 17 -40 -29 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -63 -44 -50 -221 17 -39 -28 -44
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.71 5.71 8.91
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.71 5.84 9.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 17.92 2.30 0.00 28.87 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 3.16 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 31.68% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.88 0.00 18.26 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 72.22 7.14 0.00 23.57 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 19.62 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 19.62 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 129.44 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 3.81 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.33 0.66 0.74 -1.16 0.18 0.26 0.09 0.09
Long-Term Debt to Equity		 0.00 0.30 0.45 0.36 -1.16 0.18 0.00 0.09 0.00
Financial Leverage		 0.00 -0.51 -0.40 0.18 0.51 -1.11 -0.91 -1.06 -1.05
Leverage Ratio		 0.00 1.54 1.71 2.11 6.10 2.61 1.46 1.41 1.28
Compound Leverage Factor		 0.00 1.55 1.85 2.22 6.10 2.61 1.58 1.45 1.23
Debt to Total Capital		 0.00% 24.93% 39.60% 42.56% 742.81% 15.50% 20.59% 8.00% 8.32%
Short-Term Debt to Total Capital		 0.00% 2.33% 12.60% 21.60% 0.00% 0.00% 20.59% 0.00% 8.32%
Long-Term Debt to Total Capital		 0.00% 22.60% 27.00% 20.96% 742.81% 15.50% 0.00% 8.00% 0.00%
Preferred Equity to Total Capital		 0.00% 142.04% 218.39% 173.62% 6,946.54% 237.62% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -66.97% -157.99% -116.18% -7,589.35% -153.12% 79.41% 92.00% 91.68%
Debt to EBITDA		 0.00 -0.44 -0.62 -0.80 -0.11 1.27 -0.34 -0.16 -0.13
Net Debt to EBITDA		 0.00 0.68 0.18 -0.36 0.04 -6.14 1.42 1.88 1.47
Long-Term Debt to EBITDA		 0.00 -0.40 -0.42 -0.39 -0.11 1.27 0.00 -0.16 0.00
Debt to NOPAT		 0.00 -0.65 -0.89 -1.08 -0.71 -0.72 -0.35 -0.22 -0.17
Net Debt to NOPAT		 0.00 1.00 0.25 -0.49 0.25 3.48 1.44 2.67 1.94
Long-Term Debt to NOPAT		 0.00 -0.59 -0.61 -0.53 -0.71 -0.72 0.00 -0.22 0.00
Altman Z-Score		 0.00 0.00 0.00 -3.39 -14.62 -0.60 -6.19 1.70 11.66
Noncontrolling Interest Sharing Ratio		 0.00% 189.21% 246.25% 328.31% 1,161.81% 564.30% 196.28% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 6.57 2.13 1.02 3.47 7.92 3.09 6.72 5.40
Quick Ratio		 0.00 5.52 1.74 0.57 2.86 7.63 2.80 6.05 5.04
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -84 -23 -81 74 -78 -16 -21 -32
Operating Cash Flow to CapEx		 -1,294,153.94% -1,400.22% -68,056.39% -218,716.53% 0.00% -1,131.22% -375,546.15% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -57.25 -4.81 -14.00 0.00 0.00 -3.88 -7.24 -23.61
Operating Cash Flow to Interest Expense		 -165.01 -29.49 -6.08 -10.51 0.00 0.00 -11.69 -7.34 -23.97
Operating Cash Flow Less CapEx to Interest Expense		 -165.02 -31.60 -6.09 -10.51 0.00 0.00 -11.70 -7.34 -23.97
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.04 0.37 0.00 0.14 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 3.65 28.57 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.45 16.96 0.00 20.92 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 6.10 0.00 0.88 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 100.04 12.78 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 59.83 0.00 413.92 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 100.04 -47.05 0.00 -413.92 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 41 34 78 -29 18 -3.45 -2.49 -3.30
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.16 -9.06 0.00 -3.36 0.00
Increase / (Decrease) in Invested Capital		 0.00 41 -7.43 44 -107 47 -22 0.96 -0.81
Enterprise Value (EV)		 0.00 0.00 0.00 226 283 337 33 236 479
Market Capitalization		 0.00 0.00 0.00 47 70 108 88 289 543
Book Value per Share		 $0.00 $0.00 ($1.53) ($1.51) ($2.46) ($0.64) $0.09 $0.08 $0.08
Tangible Book Value per Share		 $0.00 $0.00 ($2.12) ($2.34) ($2.91) ($0.73) $0.09 $0.08 $0.08
Total Capital		 0.00 112 69 93 3.18 141 65 55 67
Total Debt		 0.00 28 27 40 24 22 13 4.39 5.54
Total Long-Term Debt		 0.00 25 19 19 24 22 0.00 4.39 0.00
Net Debt		 0.00 -43 -7.72 18 -8.43 -106 -55 -53 -64
Capital Expenditures (CapEx)		 0.00 3.10 0.04 0.03 0.00 0.72 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 3.99 -3.04 -0.86 -3.15 -10 -4.03 -3.15 -3.35
Debt-free Net Working Capital (DFNWC)		 0.00 75 32 21 29 117 64 54 66
Net Working Capital (NWC)		 0.00 72 23 0.74 29 117 51 54 61
Net Nonoperating Expense (NNE)		 3.78 9.57 10 9.52 190 -47 4.12 9.57 10
Net Nonoperating Obligations (NNO)		 0.00 -43 -7.72 25 -8.43 -100 -55 -53 -64
Total Depreciation and Amortization (D&A)		 0.04 0.05 0.05 2.09 2.18 0.00 0.89 1.06 1.09
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -80.53% -21.50% 0.00% -31.47% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 738.35% 248.31% 0.00% 542.74% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 738.35% 248.31% 0.00% 542.74% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.39) ($0.48) $0.00 $0.00 ($0.04) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 71.24M 97.96M 338.95M 0.00 0.00 659.45M 739.62M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.39) ($0.48) $0.00 $0.00 ($0.04) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 71.24M 97.96M 338.95M 584.91M 624.93M 659.45M 739.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.39) ($0.48) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 71.24M 97.96M 338.95M 584.91M 624.93M 701.29M 795.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -43 -31 -37 -33 -21 -38 -20 -33
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -847.60% -44.97% 0.00% -198.91% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -5,709.28% 36.41% 0.00% -299.98% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -188.67 -42.83 -9.07 -8.93 0.00 0.00 -9.49 -10.15 -32.79
NOPAT to Interest Expense		 -140.88 -29.09 -6.34 -6.33 0.00 0.00 -9.13 -6.90 -24.20
EBIT Less CapEx to Interest Expense		 -188.69 -44.94 -9.08 -8.94 0.00 0.00 -9.49 -10.15 -32.79
NOPAT Less CapEx to Interest Expense		 -140.89 -31.20 -6.35 -6.33 0.00 0.00 -9.13 -6.90 -24.20
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -10.55% -1.88% -0.98% -5.05% 0.00% 0.00% 0.00% -1.73% -1.97%

Quarterly Metrics And Ratios for Mereo BioPharma Group

This table displays calculated financial ratios and metrics derived from Mereo BioPharma Group's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% 15.63% -1,383.74% -146.06% 30.47%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% 14.86% -1,040.00% -139.74% 29.74%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% 13.23% -1,480.02% -3.37% -114.32%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% 25.88% -599.89% -129.69% 22.64%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 50.00% 0.00% -100.00% 0.00%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 13.59% -1.93% -382.78% -38.75%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32.45%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 92.26% -657.04% -67.81% 0.00% -36.10% -25.54% 52.58%
EBIT Q/Q Growth		 0.00% 89.93% -495.43% -64.86% 0.00% -34.83% -25.22% 51.69%
NOPAT Q/Q Growth		 0.00% 92.89% -1,018.00% 21.39% 0.00% -29.43% 26.85% -62.99%
Net Income Q/Q Growth		 0.00% 85.50% -272.99% -39.46% 0.00% -36.91% -22.41% 53.03%
EPS Q/Q Growth		 0.00% 100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 50.00%
Operating Cash Flow Q/Q Growth		 0.00% 16.15% 134.29% -355.32% 0.00% 1.09% 4.87% -25.28%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 10.77% 19.41% -139.59%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -222.99% 36.75% -35.44%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 61.89% 0.00% 162.10% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -9.16% 0.00% -1,046.80% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -9.01% 0.00% -712.80% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -12.17% 0.00% -1,074.90% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -19.46% 0.00% -910.80% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 94.48% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 111.05% 159.91% 100.17% 89.68% 96.68% 98.17% 95.97% 93.30%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -57.81% -61.49% -46.85% -62.47% -77.58%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -149.38% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -126.58% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -57.81% -61.49% -46.85% -62.47% -77.58%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% -61.49% -46.85% -62.47% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.99 -0.57 -6.35 -4.99 -6.93 -8.97 -6.56 -11
NOPAT Margin		 0.00% -6.31% 0.00% -498.96% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -7.77% -9.18% -7.96% -22.52% 6.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -9.08% - - - -16.08%
Cost of Revenue to Revenue		 0.00% 38.11% 0.00% -62.10% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 29.66% 0.00% 359.70% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 41.24% 0.00% 480.50% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 70.90% 0.00% 805.50% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -1.10 -6.52 -11 -9.26 -12 -16 -7.55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -0.82 -6.24 -10 -8.98 -12 -15 -7.28
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 5.71 10.80 6.42 8.72 8.91
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.84 11.06 6.49 8.81 9.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 28.87 46.28 504.98 632.33 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 23.57 41.88 422.48 557.36 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.09 0.11 0.06 0.08 0.09
Long-Term Debt to Equity		 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -1.05 -1.03 -1.05 -1.03 -1.05
Leverage Ratio		 0.00 0.00 0.00 1.41 1.31 1.22 1.22 1.28
Compound Leverage Factor		 0.00 0.00 0.00 1.27 1.26 1.20 1.17 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 8.00% 9.75% 5.90% 7.11% 8.32%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 9.75% 5.90% 7.11% 8.32%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 8.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 92.00% 90.25% 94.10% 92.89% 91.68%
Debt to EBITDA		 0.00 0.00 0.00 -0.16 -0.17 -0.13 -0.12 -0.13
Net Debt to EBITDA		 0.00 0.00 0.00 1.88 1.66 2.18 1.59 1.47
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.16 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.22 -0.25 -0.18 -0.20 -0.17
Net Debt to NOPAT		 0.00 0.00 0.00 2.67 2.34 3.03 2.73 1.94
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.22 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 2.61 11.02 11.48 16.62 13.27
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 0.00 0.00 6.72 4.86 6.07 6.10 5.40
Quick Ratio		 0.00 0.00 0.00 6.05 4.42 5.65 5.67 5.04
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -5.74 -5.12 -4.13 -9.89
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -18.51 -15.47 -11.69 -26.29
Operating Cash Flow to Interest Expense		 -11.56 -7.54 3.80 -19.29 -25.78 -23.88 -21.30 -25.05
Operating Cash Flow Less CapEx to Interest Expense		 -11.56 -7.54 3.80 -19.29 -25.78 -23.88 -21.30 -25.05
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.14 0.18 0.01 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 20.92 27.78 2.96 3.17 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.88 1.05 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 413.92 348.13 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -413.92 -348.13 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -2.49 -1.19 -3.85 -2.44 -3.30
Invested Capital Turnover		 0.00 0.00 0.00 -4.02 -16.78 -0.52 -0.82 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -1.19 -3.85 -2.44 -0.81
Enterprise Value (EV)		 0.00 0.00 0.00 236 419 422 557 479
Market Capitalization		 88 165 161 289 463 505 632 543
Book Value per Share		 $0.00 $0.00 $0.00 $0.08 $0.06 $0.11 $0.09 $0.08
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $0.08 $0.06 $0.11 $0.09 $0.08
Total Capital		 0.00 0.00 0.00 55 47 84 78 67
Total Debt		 0.00 0.00 0.00 4.39 4.63 4.93 5.55 5.54
Total Long-Term Debt		 0.00 0.00 0.00 4.39 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -53 -44 -83 -75 -64
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -3.15 -1.54 -4.03 -2.46 -3.35
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 54 47 83 78 66
Net Working Capital (NWC)		 0.00 0.00 0.00 54 42 78 73 61
Net Nonoperating Expense (NNE)		 4.09 1.18 0.18 4.12 2.02 3.29 8.44 -3.65
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -53 -44 -83 -75 -64
Total Depreciation and Amortization (D&A)		 0.23 0.27 0.28 0.28 0.28 0.26 0.28 0.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -31.47% -15.38% -402.60% -245.60% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 542.74% 471.22% 8,340.50% 7,806.60% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 542.74% 424.92% 7,847.40% 7,251.50% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.01) ($0.01) ($0.02) ($0.02) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 659.45M 700.26M 711.77M 770.15M 739.62M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.01) ($0.01) ($0.02) ($0.02) ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 659.45M 700.26M 711.77M 770.15M 739.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 701.29M 701.36M 769.26M 775.73M 795.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.99 -0.57 -6.35 -4.99 -6.93 -8.97 -6.56 -11
Normalized NOPAT Margin		 0.00% -6.31% 0.00% -498.96% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -19.46% 0.00% -964.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -13.59 -1.06 -9.31 -30.54 -29.86 -37.71 -44.28 -20.09
NOPAT to Interest Expense		 -9.98 -0.55 -9.07 -14.18 -22.35 -27.10 -18.59 -28.44
EBIT Less CapEx to Interest Expense		 -13.59 -1.06 -9.31 -30.54 -29.86 -37.71 -44.28 -20.09
NOPAT Less CapEx to Interest Expense		 -9.98 -0.55 -9.07 -14.18 -22.35 -27.10 -18.59 -28.44
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -1.73% 0.00% 0.00% 0.00% -1.97%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Mereo BioPharma Group (NASDAQ:MREO) based on the last four years of quarterly data provided (Q1–Q4 2024, plus select 2023 quarters). The notes focus on cash flow, income, and balance sheet trends relevant to retail investors.

  • Q2 2024 financing activities provided a strong cash inflow of about $46.8 million, bolstering liquidity.
  • Cash and cash equivalents remained robust around $80.5 million at 9/30/2024 (Q3 2024), with higher levels earlier in 2024, indicating solid liquidity runway.
  • Long-Term Debt stood at $0.0 as of Q3 2024, indicating a low-leverage balance sheet.
  • Total equity was about $72.5 million as of Q3 2024, providing a cushion to support ongoing operations.
  • Other income / (expense), net contributed approximately $7.73 million in Q4 2024, helping offset operating losses.
  • Revenue remains largely non-existent in recent quarters (operating revenue and total revenue around zero), consistent with a pre-revenue biotech profile.
  • Weighted-average shares outstanding increased meaningfully by year-end 2024, signaling potential dilution for existing shareholders.
  • The company posted persistent quarterly losses, including roughly -$15.0 million in Q3 2024 and -$7.05 million in Q4 2024 (also -$12.25 million in Q2 2024 and -$8.95 million in Q1 2024).
  • Operating cash flow was negative in all 2024 quarters, with net cash from continuing operating activities around -$7.9 million to -$9.1 million per quarter, signaling ongoing cash burn.
  • Cumulative retained earnings remained deeply negative (about -$456 million as of Q3 2024), highlighting long-standing deficits.
05/14/26 06:25 AM ETAI Generated. May Contain Errors.

Mereo BioPharma Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mereo BioPharma Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Mereo BioPharma Group's net income appears to be on a downward trend, with a most recent value of -$43.25 million in 2024, rising from -$35.03 million in 2016. The previous period was -$29.47 million in 2023. See where experts think Mereo BioPharma Group is headed by visiting Mereo BioPharma Group's forecast page.

Mereo BioPharma Group's total operating income in 2024 was -$47.36 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $47.36 million

Over the last 8 years, Mereo BioPharma Group's total revenue changed from $0.00 in 2016 to $0.00 in 2024, a change of 0.0%.

Mereo BioPharma Group's total liabilities were at $15.42 million at the end of 2024, a 3.4% decrease from 2023, and a 66.3% decrease since 2017.

In the past 7 years, Mereo BioPharma Group's cash and equivalents has ranged from $21.66 million in 2019 to $127.30 million in 2021, and is currently $69.80 million as of their latest financial filing in 2024.

Over the last 8 years, Mereo BioPharma Group's book value per share changed from 0.00 in 2016 to 0.08 in 2024, a change of 7.9%.


Related Companies

Financial statements for NASDAQ:MREO last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
One coin wired into Elon's vision
The Kevin Warsh Fed takeover is here. And he's brought a thesis with him that almost nobody is talking about. ...
Crypto 101 Media | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Is this AI lab Elon’s SpaceX lifeline?
Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...
Chaikin Analytics | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Millionaire trader: “Buy this before May 15.”
Hedge fund legend Larry Benedict - who beat the S&P 500 by 18 times in 2025 and generated $95 million for clie...
Brownstone Research | Sponsoredtc pixel